Annual Monitoring for Patients on Persistent Medications (MPM)

Assesses adults 18 years and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and received at least one therapeutic monitoring event for the therapeutic agent during the measurement year:

  • Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).
  • Annual monitoring for members on diuretics.
  • Total rate (sum of the two numerators divided by the sum of the two denominators).

Why It Matters

Adverse drug events cause more than 1.3 million visits to the ED each year.1 The more medications people take, the higher their risk of having an adverse drug event.1 Adverse drug events contribute to patient injury and increased health care costs. For patients on persistent medications, appropriate monitoring can reduce the occurrence of preventable adverse drug events.

Results

MEDICATION RECONCILIATION POST-DISCHARGE
CommercialMedicaidMedicare
YearHMOPPOHMOHMOPPO
2017______52.553.3
2016______46.147.5

References

  1. Centers for Disease Control and Prevention. 2018. “Adults and Older Adult Adverse Drug Events.” http://www.cdc.gov/MedicationSafety/Adult_AdverseDrugEvents.html

  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.